<i>DPYD</i> c.1905 + 1G&gt;A Promotes Fluoropyrimidine-Induced Anemia, a Prognostic Factor in Disease-Free Survival, in Colorectal Cancer.

Deligonul A., Aksoy S., Tezcan G., Tunca B., Kanat O., Cubukcu E., ...Daha Fazla

Genetic testing and molecular biomarkers, cilt.25, sa.4, ss.276-283, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 4
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1089/gtmb.2020.0285
  • Dergi Adı: Genetic testing and molecular biomarkers
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.276-283
  • Anahtar Kelimeler: DPYD c.1905+1G > A, fluoropyrimidine, anemia, colorectal cancer
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background and Aim: In 10-30% of colorectal cancer (CRC) patients, toxic reactions occur after fluoropyrimidine-based chemotherapy. A dihydropyridine dehydrogenase (DPYD) gene variant, c.1905 + 1G>A, leads to intolerance to fluoropyrimidines. Due to the low frequency of this variant in many populations, the prevalence of fluoropyrimidine-induced hematologic side effects in CRC patients with the c.1905 + 1G>A variant is unclear. In this study, we investigated the prevalence of the DPYD c.1905 + 1 variants in a Turkish CRC cohort and the potential effects of these variants on fluoropyrimidine-induced hematologic side effects.